| Literature DB >> 24626165 |
Jie Lou1, Meridith Blevins2, Yuhua Ruan3, Sten H Vermund4, Sanyi Tang5, Glenn F Webb6, Bryan E Shepherd2, Xiong He7, Hongyan Lu7, Yiming Shao3, Han-Zhu Qian8.
Abstract
OBJECTIVE: To project the HIV/AIDS epidemics among men who have sex with men (MSM) under different combinations of HIV testing and linkage to care (TLC) interventions including antiretroviral therapy (ART) in Beijing, China.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24626165 PMCID: PMC3953201 DOI: 10.1371/journal.pone.0090985
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Schematic diagram of HIV combination prevention intervention model in the presence of ART.
The top row of compartments show uninfected MSM who are Susceptible to HIV infection. They are divided into Non-testers, Testers, and testers who received Risk reduction and linkage-to-care interventions. The bottom two rows representing two stages of disease contain an additional compartment—Infected individuals. Stage 1 is CD4+ cell count <350/µL while stage 2 is CD4+ ≥350/µL. The last column of compartments shows HIV-infected individuals who have initiated Antiretroviral therapy. is the recruitment rate per year into the MSM population in Beijing. They are local HIV- MSM who turn 18 years old, or those from other areas who immigrate to Beijing. Horizontal movement is parameterized by rates of testing (), rates of linkage to care (), rates of ART initiation (), and rates of ART failure or dropout (). Movement from Susceptible to Infected () is the HIV transmission rate. It is estimated from multiple parameters including condom use, insertive/receptive intercourse, regular/casual partner encounter, CD4 count, and reductions in infectivity due to TLC or ART. The natural removal rate () represents death, being older than 60 years, or migration out of Beijing. The rate of disease progression is different for HIV-infected individuals on ART () or not on ART ().
The notation, description, value and uncertainty range of parameters and their data sources for the mathematical model.
| Parameter | Description | Value | Uncertainty range | Source | |
| Initial conditions |
| No. of non-tested susceptible MSM | 102,271 | ||
|
| No. of tested susceptible MSM | 128 | |||
|
| No. of risk reduction (RR) susceptible MSM | 0 | |||
|
| No. of non-tested MSM+ in infection stage 1 | 828 | |||
|
| No. of non-tested MSM+ in infection stage 2 | 414 | |||
|
| No. of tested MSM+ | 1 | |||
|
| No. of RR MSM+ | 0 | |||
|
| No. of MSM+ on antiretroviral therapy (ART) | 0 | |||
| Progression |
| Recruitment rate into target population per year | 5,012 | 2,073–6,633 | Fit |
|
| Natural removal rate of MSM− per year | 0.024 | - |
| |
|
| Progression rate of MSM+ without ART | 0.18 | - |
| |
|
| Progression rate of MSM+ with ART | 0.089 | - |
| |
| Sex and condoms |
| No. of anal intercourse (AI) for non-tested MSM+ with RP | 36.5 | 32.2–40.1 |
|
|
| No. of AI for tested/RR HIV− with RP | 36.2 | 34.9–38.6 |
| |
|
| No. of AI for non-tested HIV− with CP | 18.2 | 11.3–21.7 |
| |
|
| No. of AI for tested/RR HIV− with CP | 22.2 | 20.9–24.6 |
| |
|
| Condom use among non-tested MSM with RP | 30.7% | 28.0–36.7% |
| |
|
| Condom use among tested/RR MSM with RP | 31.6% | 23.8–37.2% |
| |
|
| Condom use among non-tested MSM with CP | 37.7% | 34.5–42.3% |
| |
|
| Condom use among tested/RR MSM with CP | 41.4% | 37.0–43.7% |
| |
| Transmission |
| Relative infectiousness (RI) of tested MSM+ to non-tested MSM+ | 0.74 | 0–1 |
|
|
| RI of RR MSM+ to non-tested MSM+ | 0.48 | 0–1 | Fit | |
|
| RI of MSM+ on ART to not on ART | 0.4 | 0.01–.4 |
| |
|
| RI of MSM+ in infection stage 2 to stage 1 | 1.63 | 0.5–3 | Fit | |
|
| New infections due to unprotected receptive AI | 0.016 | 0.008–0.028 | Fit | |
|
| New infections due to unprotected insertive AI | 0.0012 | 0.0006–0.0019 | Fit | |
|
| Sex acts of insertive AI | 0.56 | 0.50–0.61 | Fit | |
| Intervention uptake |
| Testing rates among MSM− or MSM+ | 0.09 | 0.05–0.20 |
|
|
| Linkage to risk reduction (RR) rate among MSM− | 0.19 | 0.10–0.25 | Fit | |
|
| Linkage to risk reduction (RR) rates among MSM+ | 0.33 | 0.25–0.5 |
| |
|
| ART initiation rate among linked MSM+ in their infection stage 1 | 0.018 | 0.005–0.036 |
| |
|
| ART initiation rate among linked MSM+ in their infection stage 2 | 0.53 | 0.44–0.62 |
| |
|
| ART dropout rate | 0.024 | - |
| |
|
| Immunological recovery on ART | 0.50 | 0–1 | Fit |
Note: MSM+: HIV-infected MSM; MSM+: HIV-uninfected MSM; RP: regular sexual partner; CP: casual sexual partner.
Figure 2Predicted effects on HIV prevalence and incidence among Chinese MSM in five scenarios of HIV combination interventions.
(A) effect on HIV prevalence; (B) effect on HIV incidence.
Figure 3Contour plots: the effects on under different coverage rates of HIV testing and risk reduction interventions among HIV-infected Chinese MSM while condom use remains at the average level of years 2000–2010.
(A) Under the different coverage rates of HIV testing intervention; (B) Under the different coverage rates of HIV risk reduction (RR) intervention.